Stelac Advisory Services LLC bought a new stake in shares of Sanofi (NASDAQ:SNY – Free Report) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 56,555 shares of the company’s stock, valued at approximately $2,326,000.
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Bank of America Corp DE raised its position in shares of Sanofi by 11.0% in the 1st quarter. Bank of America Corp DE now owns 9,484,350 shares of the company’s stock valued at $456,956,000 after purchasing an additional 940,342 shares during the last quarter. Mondrian Investment Partners LTD boosted its position in Sanofi by 2.3% in the third quarter. Mondrian Investment Partners LTD now owns 5,652,139 shares of the company’s stock valued at $233,038,000 after buying an additional 129,575 shares during the last quarter. Royal Bank of Canada boosted its position in Sanofi by 17.5% in the first quarter. Royal Bank of Canada now owns 3,155,080 shares of the company’s stock valued at $152,011,000 after buying an additional 470,882 shares during the last quarter. Equity Investment Corp boosted its position in Sanofi by 1.3% in the third quarter. Equity Investment Corp now owns 2,636,859 shares of the company’s stock valued at $108,718,000 after buying an additional 34,888 shares during the last quarter. Finally, Regal Partners Ltd increased its holdings in Sanofi by 33.2% in the 1st quarter. Regal Partners Ltd now owns 2,545,432 shares of the company’s stock worth $122,639,000 after buying an additional 633,782 shares during the period. 14.03% of the stock is currently owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
SNY has been the subject of a number of recent research reports. Royal Bank Of Canada assumed coverage on shares of Sanofi in a research report on Tuesday, September 8th. They set a “sector perform” rating for the company. Berenberg Bank restated a “buy” rating on shares of Sanofi in a research note on Monday, October 5th. BNP Paribas Exane raised shares of Sanofi from a “neutral” rating to an “outperform” rating and set a $57.00 price objective on the stock in a report on Monday, November 9th. Wall Street Zen upgraded shares of Sanofi from a “hold” rating to a “buy” rating in a research note on Saturday, November 7th. Finally, DZ Bank reissued a “buy” rating on shares of Sanofi in a report on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and twelve have assigned a Hold rating to the company. According to data from MarketBeat, Sanofi presently has a consensus rating of “Hold” and an average price target of $53.00.
View Our Latest Stock Analysis on Sanofi
Sanofi Trading Down 1.8%
Sanofi stock opened at $47.53 on Wednesday. The company has a current ratio of 1.12, a quick ratio of 0.27 and a debt-to-equity ratio of 0.20. Sanofi has a 12 month low of $39.07 and a 12 month high of $50.94. The stock’s 50 day simple moving average is $42.85 and its two-hundred day simple moving average is $44.39. The firm has a market cap of $115.23 billion, a PE ratio of 23.53, a P/E/G ratio of 1.33 and a beta of 0.31.
Sanofi (NASDAQ:SNY – Get Free Report) last issued its quarterly earnings data on Friday, October 30th. The company reported $2.04 EPS for the quarter, topping analysts’ consensus estimates of $1.56 by $0.48. The business had revenue of $17.25 billion for the quarter, compared to analysts’ expectations of $14.30 billion. Sanofi had a net margin of 8.70% and a return on equity of 15.16%. The business’s revenue was up 16.2% on a year-over-year basis. During the same quarter last year, the company earned $2.91 EPS. Analysts anticipate that Sanofi will post 5.07 earnings per share for the current year.
Sanofi Profile
Sanofi is a France-based global biopharmaceutical company that researches, develops, manufactures and markets medicines and vaccines. Its work spans areas including immunology, oncology, rare diseases and neurology, as well as preventive vaccines. The company’s portfolio includes Dupixent, an immunology medicine developed with Regeneron, and vaccines for diseases such as influenza and meningitis. Sanofi serves patients and healthcare providers in markets around the world. Sanofi traces its origins to a company established in France in 1973.
Read More
- Five stocks we like better than Sanofi
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NASDAQ:SNY – Free Report).
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.
